Patients with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer had better responses to treatment after receiving primary chemoablation with UGN-102, a nonsurgical treatment ...
In an interview, Antoni Vilaseca Cabo, MD, discussed the clinical activity of TAR-210 in patients with non-muscle invasive ...
New and Recurrent Patients Treated with UGN-102 Achieved Similar Durability of Response Rates (DOR) at 12 months PRINCETON, N.J--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback